IBI has recently completed the acquisition of NuPep!

January 27, 2020
corticalis ibi

IBI has recently completed the acquisition of NuPep!

IBI has recently completed the acquisition, from the Norwegian company Corticalis, of the patents bundle on “consensus peptides”, commercially traded under the name “NuPep”.

In brief, NuPeps are a library of synthetic intrinsically disordered peptides, first in class having being granted a patent on, that possess signaling properties useful in various tissues regeneration applications.

“This technological platform well complements IBI’s portfolio and allows us to further expand our researches and developments towards next generation of orthobiologics and new regenerative medicine products too”, commented Prof. Dr. Giuseppe Perale, IBI executive Vice President for clinical and scientific affairs and one of the company founders.

Contacts

IBI S.A.
Industrie Biomediche Insubri S.A.
via Cantonale 67, CH-6805 Mezzovico-Vira, Switzerland
t. +41 91 93.06.640
f. +41 91 220.70.00